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Appendix: Quality of Health Economic Studies Framework 1 
Number Question text Scoring 
1 
Was the study objectively presented in a clear, specific, and 
measurable manner? 
Clear, specific, measurable =7 
Any two = 5 
Any one = 2 
None = 0 
2 
Was the perspective of the analysis (societal, third party, payer, 
etc.) and reasons for its selection stated? 
Perspective = 2 
Reasons = 2 
Both = 4 
3 
Were variable estimates used in the analysis from the best 
available source (i.e., randomized control trial - best, expert 
opinion - worst)? 
Randomized control trial = 8 
Non-Randomized control trial 
= 7 
Cohort studies = 6 
Case-control/case report 
/case series = 4 
Expert opinion = 2 
4 
If estimates came from a subgroup analysis, were the groups 
prespecified at the beginning of the study? 
Yes = 1 
No = 0 
5 
Was uncertainty handled by (1) statistical analysis to address 
random events, (2) sensitivity analysis to cover a range of 
assumptions? 
Statistical analysis = 4.5 
Sensitivity analysis = 4.5 
Both = 9 
6 
Was incremental analysis performed between alternatives for 
resources and costs? 
Yes = 6 
No = 0 
CCA type of economic 
evaluation = NA 
7 
Was the methodology for data extraction (including the value 
of health states and other benefits) stated? 
Yes = 5 
No = 0 
2 
 
Number Question text Scoring 
8 
Did the analytic horizon allow time for all relevant and 
important outcomes? Were benefits and costs that went 
beyond 1 year discounted (3% to 5%) and justification given for 
the discount rate? 
(1) Time horizon = 3 
(2) Cost discounting = 1 
(3) Benefit discounting = 1 
(4) Justification = 2 
All but justification = 5 
All = 7 
9 
Was the measurement of costs appropriate and the 
methodology for the estimation of quantities and unit costs 
clearly described? 
(1) appropriateness of cost 
measurement = 4 
(2) clear description of 
methodology for the 
estimation of quantities = 2 
(3) clear description of 
methodology for the 
estimation of unit costs = 2 
All = 8 
10 
Were the primary outcome measure(s) for the economic 
evaluation clearly stated and did they include the major short-
term? Was justification given for the measures/scales used? 
(1) primary outcome clearly 
stated = 2 
(2) include major short-term 
outcome = 2 
(3) justification = 2 
All = 6 
11 
Were the health outcomes measures/scales valid and reliable? 
If previously tested valid and reliable measures were not 
available, was justification given for the measures/scales used? 
Yes = 7 
No = 0 
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Number Question text Scoring 
12 
Were the economic model (including structure), study methods 
and analysis, and the components of the numerator and 
denominator displayed in a clear, transparent manner? 
(1) economic model = 2 
(2) study methods = 1.5 
(3) analysis = 1.5 
(4) components of numerator 
= 1.5 
(5) components of 
denominator = 1.5 
All = 8 
If not a modelling study, 
done for 
(1) study methods = 2 
(2) analysis = 2 
(3) components of numerator 
= 2 
(4) components of 
denominator = 2 
All=8 
13 
Were the choice of economic model, main assumptions, and 
limitations of the study stated and justified? 
(1) economic model = 2 
(2) assumptions = 2.5 
(3) limitations = 2.5 
All = 7 
If not a modelling study, 
done (stated and justified) 
for 
(1) assumptions = 3.5 
(2) limitations = 3.5 
Both = 7 
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Number Question text Scoring 
14 
Did the author(s) explicitly discuss direction and magnitude of 
potential biases? 
(1) direction = 3 
(2) magnitude = 3 
Both = 6 
15 
Were the conclusions/recommendations of the study justified 
and based on the study results? 
Yes = 8 
No = 0 
16 
Was there a statement disclosing the source of funding for the 
study? 
Yes = 3 
No = 0 
 2 
 3 
SEARCH 1: economic or evaluation or cost effect* or “cost saving” AND improv* or "behavior change" or 
"willingness to change" or accept* or "roll out" or change or adhere* AND "clinical guideline*" or "education 
outreach" or evidence or "evidence based" or "quality improv*" or "service improv* or "local impl*" AND 
clinical or doctor or nurse or "allied health professionals" or clinician or pathway or "decision make*" or "local 
govern*" or "clinical commiss*" or "commissioners" 
o Including Limited Related Terms 
SEARCH 2: economic or evaluation or “cost effect*” or “cost saving” AND improv* or "behavior change" or 
"willingness to change" or accept* or "roll out" or change or adhere* AND "clinical guideline*" or "education 
outreach" or evidence or "evidence based" or "quality improv*" or "service improv* or "local impl*" AND 
clinical or doctor or nurse or "allied health professionals" or clinician or pathway or "decision make*" or "local 
govern*" or "clinical commiss*" or "commissioners" 
o Including related terms 
SEARCH 3: search 1 without related terms 
SEARCH 4: search 2 without related terms 
 Cost-consequences analysis (CCA): compares costs and multiple measures of patient outcome of 
alternatives under evaluation.  
Cost-effectiveness analysis (CEA): compares costs and outcomes of alternatives using a single 
primary measure of patient outcome (e.g. life-years gained; cases of disease avoided; 
improvements in clinical functioning; improvements in quality of care experience).  
Cost-utility analysis (CUA):  compares costs and outcomes of alternatives with outcomes 
measured as quality-adjusted life years (QALYs) gained.  
Cost-benefit analysis (CBA):  compares costs and outcomes of alternatives, with patient outcomes 
valued monetarily.    
Cost-analysis (CA): Costs implications only of relevant alternatives evaluated with no consideration 
of impact on quality of care and patient outcomes (not strictly a full economic evaluation).   
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Additional records identified 
through other sources 
(n =  0) 
Records after duplicates removed 
(n =  1596 ) 
Records screened 
(n = 1596) 
Records excluded 
(n = 1525) 
Full-text articles 
assessed for eligibility 
(n = 71) 
Full-text articles 
excluded 
(n = 41) 
Studies included in final 
qualitative synthesis 
(n = 30) 
Table 1 – Panel 1a: improvement studies  
Author Year Country Improvement or 
Implementation focus  
Care setting Improvement 
intervention focus 
Sample size Main study outcomes Type of 
economic 
analysis 
Quality 
appraisal 
score for 
economic 
modelling (out 
of 100) 
Afzali et al 2013 Australia Improvement Endocrinology Staff mix 
reformulation 
(Nurse-led) 
3642 EQ-5D (EuroQol 5 
dimension scale) 
CEA 100 
Albers-Heitner et al 2010 Netherlands Improvement Primary Care Staff mix 
reformulation 
(Nurse-led) 
384 EQ-5D CEA 74 
Bauer 2010 USA Improvement N/A Staff mix 
reformulation 
(Nurse-led) 
160 Resource use CEA N/A 
Dawes et al 2007 UK Improvement Gynaecology Staff mix 
reformulation 
(Nurse-led) 
111 SF-36 (36-Item Short 
Form Health Survey), 
Length of Stay 
CCA 66.5 
Faulkener et al 2003 UK Improvement Primary Care Improved referral N/A Review Review N/A 
Furze et al 2011 UK Improvement Cardiology Staff mix 
reformulation (peer 
support) 
142 EQ-5D CUA 84.5 
Hernandez et al 2014 UK Improvement Intensive Care Staff mix 
reformulation 
(Nurse-led) 
286 EQ-5D CUA 90.5 
Karnon et al 2016 Australia Improvement Cardiology Service 
Reconfiguration 
(funding sources) 
603 N/A CCA 44.5 
Kilpatrick et al 2014 Canada Improvement Hospital General 
Medicine 
Staff mix 
reformulation 
(Nurse-led) 
2147 Review CEA N/A 
Latour et al 2007 Netherlands Improvement Hospital wards Staff mix 
reformulation 
(Nurse-led) 
208 SF-36, HADS (Hospital 
Anxiety and 
Depression Scale) 
CEA 81.5 
Mdege et al 2012 Sub-Saharan 
Africa 
Improvement HIV Staff mix 
reformulation 
(multiple scenarios) 
19767 N/A Review N/A 
Tappenden et al 2012 UK Improvement Geriatrics Staff mix 
reformulation 
(Nurse-led) 
N/A Review CEA N/A 
Walsh et al 2005 UK Improvement General Medicine Staff mix 
reformulation 
(Nurse-led) 
238 Bed days CA 65 
Williams et al 2006 UK Improvement Gastroenterology Staff mix 
reformulation 
(Nurse-led) 
1500 EQ-5D CEA 94 
Williams et al 2005 UK Improvement Urology Staff mix 
reformulation 
(Nurse-led) 
3746 EQ-5D CEA 51 
Yarbrough et al 2015 USA Improvement General Medicine New pathway 677 Resource use CEA N/A 
Note: CEA: Cost-Effectiveness Analysis; CUA: Cost-Utility analysis; CCA: cost-consequences analysis; CA: cost analysis 
 
Panel 1b: implementation studies  
Author Year Country Improvement or 
Implementation focus  
Care setting Implementation 
intervention focus  
Main study 
outcomes 
Type of 
economic 
evaluation 
Sample size Quality appraisal 
score for economic 
modelling (out of 
100) 
Brunenberg et al 2005 Netherlands Implementation Orthopaedics Pathway 
implementation 
EQ-5D, Length 
of stay 
CEA 160 71 
Burr et al 2007 UK Implementation Ophthalmology Screening programme 
implementation 
EQ-5D CUA 207-32918 89.5 
Burr et al 2012 UK Implementation Ophthalmology Surveillance programme 
implementation 
EQ-5D, 
Willingness to 
pay 
CUA 800 92.5 
Judd et al 2014 USA Implementation Hospital wards Early intervention 
implementation 
Length of Stay CA 181 37 
Kifle et al 2010 Ethiopia Implementation All hospital specialities Referral system 
implementation 
Resource use CEA 532 N/A 
Maloney et al 2012 Australia Implementation Physiotherapy Health professional 
education 
Costs only CEA 85 94.5 
Mortimer et al 2013 Australia Implementation General Practice Implementation 
methods (active vs 
guideline dissemination)  
EQ-5D, X rays 
avoided 
CEA 112 81.5 
Purshouse et al 2013 UK Implementation Public Health Screening programme 
implementation 
EQ-5D CEA N/A 82 
Rachev 2015 USA Implementation Public Health General methods of 
health service 
transformation  
Resource use CEA N/A N/A 
Robertson et al 2011 UK Implementation Oncology Surveillance programme 
implementation 
EQ-5D CUA N/A 94 
Tappenden et al 2013 UK Implementation Oncology Resource allocation 
decision making 
EQ-5D CUA N/A 84 
Umscheid et al 2010 Canada Implementation N/A Comparative 
effectiveness centre 
None Review N/A N/A 
Vestergaard et al 2015 Denmark Implementation Cardiology Guideline adherence vs 
observed treatment 
EQ-5D CEA N/A 57.5 
Yee & Shafie 2013 Malaysia Implementation Respiratory Asthma management 
implementation 
EQ-5D Review N/A N/A 
 
Improvement or Implementation interventions across studies (N of studies & %) 
Staffing reconfiguration 13 43% 
Pathway implementation 4 14% 
Review of practice 3 10% 
Improvement in patient screening 3 10% 
Service reconfiguration 2 7% 
Improvement in follow up procedures 2 7% 
Monitoring activity 1 3% 
Guideline adherence 1 3% 
Education 1 3% 
 
Study  Costs considered Scenarios considered Conclusion: 
Intervention cost-
effective? 
Furze et al 2011 Training costs None Yes 
Judd et al 2014 None Scaling scenarios Yes 
Kifle et al 2010 Indirect costs of 
patients and carers; 
Project costs; 
Impacts on staff 
None Yes 
Maloney et al 2012 Training and set up 
costs 
Roll out scenarios Yes 
Mdege et al 2012 Training costs Roll out scenarios Yes 
Mortimer et al 2013 Development costs; 
Amortisation; 
Delivery costs; 
Roll out costs 
Roll out scenarios No 
Purshouse et al 2013 None Roll out scenarios Yes, although 
sensitive to rollout 
costs 
Rachev 2015 Outlining of costs None Inconclusive 
Tappenden et al 2013 None Funding scenarios N/A 
 
QHES Dimension Average score 
Highest 
possible 
score 
Percentage achieving highest 
possible score 
Was the study objective presented in a clear, specific, and measurable manner? 6.0 7 65% 
Were the perspective of the analysis (societal, thirdparty, payer, etc.) and reasons for its 
selection stated? 2.4 4 28% 
Were variable estimates used in the analysis from the best available source (i.e., randomized 
control trial - best, expert opinion - worst)? 
7.4 8 83% 
If estimates came from a subgroup analysis, were the groups prespecified at the beginning of 
the study? 
0.4 1 33% 
Was uncertainty handled by (1) statistical analysis to address random events, (2) sensitivity 
analysis to cover a range of assumptions? 
5.8 9 33% 
Was incremental analysis performed between alternatives for resources and costs? 5.4 6 94% 
Was the methodology for data extraction (including the value of health states and other 
benefits) stated? 
4.0 5 78% 
Did the analytic horizon allow time for all relevant and important outcomes? Were benefits 
and costs that went beyond 1 year discounted (3% to 5%) and justification given for the 
discount rate? 
4.7 7 39% 
Was the measurement of costs appropriate and the methodology for the estimation of 
quantities and unit costs clearly described? 
3.9 8 0% 
Were the primary outcome measure(s) for the economic evaluation clearly stated and did 
they include the major short-term? Was justification given for the measures/scales used? 
4.7 6 67% 
Were the health outcomes measures/scales valid and reliable? If previously tested valid and 
reliable measures were not available, was justification given for the measures/scales used? 
5.0 7 72% 
Were the economic model (including structure), study methods and analysis, and the 
components of the numerator and denominator displayed in a clear, transparent manner? 
6.7 8 83% 
Were the choice of economic model, main assumptions, and limitations of the study stated 
and justified? 
5.6 7 78% 
Did the author(s) explicitly discuss direction and magnitude of potential biases? 3.9 6 56% 
Were the conclusions/recommendations of the study justified and based on the study 
results? 
8.0 8 100% 
Was there a statement disclosing the source of funding for the study? 2.4 3 78% 
 
